ArticleVeterinary sciences2026
Immunohistochemical Characterization of 14-3-3σ Expression in Canine Primary Pulmonary Carcinomas: A Preliminary Study.
Article in Veterinary sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
14-3-3σ is a cell-cycle regulatory protein implicated in tumor development and progression, but its expression in canine primary pulmonary carcinomas (CPPC) has not been characterized. This study investigated 14-3-3σ immunohistochemical expression in primary pulmonary carcinomas and its relationship with histological grade, proliferative activity, mitotic count, and tumor volume. Ten CPPCs were examined and graded according to established criteria. Immunohistochemical expression of 14-3-3σ was evaluated using a semiquantitative scoring system, while Ki-67 labeling was assessed by calculating the labeling index. Nine of 10 tumors (90%) showed 14-3-3σ immunoreactivity, which was predominantly multifocal, heterogeneous, and cytoplasmic; nuclear immunoreactivity was observed, particularly in areas showing strong cytoplasmic staining. Exploratory correlation analyses did not identify statistically significant associations between the 14-3-3σ immunohistochemical score and histological grade, Ki-67 labeling index, mitotic count, or estimated tumor volume. The Ki-67 labeling index ranged from 20.4% to 89.5% (median, 35.6%). These findings provide preliminary descriptive data on 14-3-3σ immunoreactivity in CPPCs. Larger studies incorporating quantitative assessment and clinical follow-up are warranted to determine its clinicopathological and prognostic significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.